127 related articles for article (PubMed ID: 10738106)
21. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
Monzo M; Moreno I; Navarro A; Ibeas R; Artells R; Gel B; Martinez F; Moreno J; Hernandez R; Navarro-Vigo M
Oncology; 2007; 72(5-6):364-70. PubMed ID: 18204222
[TBL] [Abstract][Full Text] [Related]
22. Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer.
Lin K; Ye D; Xie X
Int J Gynecol Cancer; 2008; 18(5):1007-12. PubMed ID: 18081788
[TBL] [Abstract][Full Text] [Related]
23. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.
Li Q; Yu JJ; Mu C; Yunmbam MK; Slavsky D; Cross CL; Bostick-Bruton F; Reed E
Anticancer Res; 2000; 20(2A):645-52. PubMed ID: 10810335
[TBL] [Abstract][Full Text] [Related]
24. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.
Ferry KV; Hamilton TC; Johnson SW
Biochem Pharmacol; 2000 Nov; 60(9):1305-13. PubMed ID: 11008124
[TBL] [Abstract][Full Text] [Related]
25. DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes.
Vogel U; Dybdahl M; Frentz G; Nexo BA
Mutat Res; 2000 Nov; 461(3):197-210. PubMed ID: 11056291
[TBL] [Abstract][Full Text] [Related]
26. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues.
Yu JJ; Mu C; Lee KB; Okamoto A; Reed EL; Bostick-Bruton F; Mitchell KC; Reed E
Mutat Res; 1997 Sep; 382(1-2):13-20. PubMed ID: 9360634
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of open complex and dual incision formation by human nucleotide excision repair factors.
Evans E; Moggs JG; Hwang JR; Egly JM; Wood RD
EMBO J; 1997 Nov; 16(21):6559-73. PubMed ID: 9351836
[TBL] [Abstract][Full Text] [Related]
28. Xeroderma pigmentosum and molecular cloning of DNA repair genes.
Boulikas T
Anticancer Res; 1996; 16(2):693-708. PubMed ID: 8687116
[TBL] [Abstract][Full Text] [Related]
29. The formation of UV-induced chromosome aberrations involves ERCC1 and XPF but not other nucleotide excision repair genes.
Chipchase MD; Melton DW
DNA Repair (Amst); 2002 Apr; 1(4):335-40. PubMed ID: 12509251
[TBL] [Abstract][Full Text] [Related]
30. Regulation of DNA repair gene expression in human cancer cell lines.
McGurk CJ; Cummings M; Köberle B; Hartley JA; Oliver RT; Masters JR
J Cell Biochem; 2006 Apr; 97(5):1121-36. PubMed ID: 16315315
[TBL] [Abstract][Full Text] [Related]
31. Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells.
Koeppel F; Poindessous V; Lazar V; Raymond E; Sarasin A; Larsen AK
Clin Cancer Res; 2004 Aug; 10(16):5604-13. PubMed ID: 15328203
[TBL] [Abstract][Full Text] [Related]
32. Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon and lung carcinomas: implication for their roles of carcinogenesis in human solid tumors.
Takebayashi Y; Nakayama K; Kanzaki A; Miyashita H; Ogura O; Mori S; Mutoh M; Miyazaki K; Fukumoto M; Pommier Y
Cancer Lett; 2001 Dec; 174(2):115-25. PubMed ID: 11689286
[TBL] [Abstract][Full Text] [Related]
33. An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin.
Goldberg Z; Evans J; Birrell G; Brown JM
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):175-82. PubMed ID: 11163512
[TBL] [Abstract][Full Text] [Related]
34. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.
Wang QE; Milum K; Han C; Huang YW; Wani G; Thomale J; Wani AA
Mol Cancer; 2011 Mar; 10():24. PubMed ID: 21385444
[TBL] [Abstract][Full Text] [Related]
35. [ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs].
Bogush TA; Popova AS; Dudko EA; Bogush EA; Tyulyandina AS; Tyulyandin SA; Davydov MI
Antibiot Khimioter; 2015; 60(3-4):42-50. PubMed ID: 26415382
[TBL] [Abstract][Full Text] [Related]
36. The association of polymorphisms in nucleotide excision repair genes with ovarian cancer susceptibility.
Zhao Z; Zhang A; Zhao Y; Xiang J; Yu D; Liang Z; Xu C; Zhang Q; Li J; Duan P
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29669843
[TBL] [Abstract][Full Text] [Related]
37. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
[TBL] [Abstract][Full Text] [Related]
38. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
[TBL] [Abstract][Full Text] [Related]
39. Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2.
Dabholkar MD; Berger MS; Vionnet JA; Egwuagu C; Silber JR; Yu JJ; Reed E
Cancer Res; 1995 Mar; 55(6):1261-6. PubMed ID: 7882319
[TBL] [Abstract][Full Text] [Related]
40. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.
Gentile F; Tuszynski JA; Barakat KH
J Mol Graph Model; 2016 Apr; 65():71-82. PubMed ID: 26939044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
